Press Releases

- I nterim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression - All eight participants...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 8, 2024-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast with management and Fumihiko Urano , MD, PhD, Principal Investigator of the HELIOS clinical trial and the Samuel E....

- Based on topline results from the Phase 3 PHOENIX trial of AMX0035 in ALS, Amylyx has started a process with the FDA and Health Canada of voluntarily discontinuing the marketing authorizations   for RELYVRIO/ALBRIOZA - RELYVRIO/ALBRIOZA will no longer be available for new patients as of today;...

- Dr. Zeiher brings more than 20 years of drug development experience in areas with serious unmet treatment needs at companies including Astellas Pharma, Pfizer, Eli Lilly and Company, and Merck CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 14, 2024-- Amylyx Pharmaceuticals, Inc....

- PHOENIX Study Did Not Meet Prespecified Primary or Secondary Endpoints - Data From 664-Participant Study Reinforce That AMX0035 is Generally Safe and Well-Tolerated - Within the Next Eight Weeks, Amylyx Will Continue to Engage With Regulatory Authorities and the ALS Community to Share Topline...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 23, 2024-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has granted stock options and restricted stock units (“RSUs”) to Linda Arsenault , the Company’s newly appointed Chief Human Resources Officer....

Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter Delivered $49.3 million in net income for the full year 2023, including $4.7 million in the fourth quarter, and ended the year with cash, cash equivalents and short-term investments...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 15, 2024-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its fourth quarter and full year 2023 financial results on Thursday, February 22, 2024 . Amylyx’ senior management team will host a conference call and audio...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 15, 2024-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that two abstracts detailing next steps in the development of the Company’s investigational antisense oligonucleotide (ASO), AMX0114, for the potential...

Preliminary results from HELIOS anticipated in the second half of 2024 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 8, 2024-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced it has completed enrollment of its Phase 2 HELIOS trial of AMX0035 (sodium phenylbutyrate...